Barclays PLC Boosts Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Barclays PLC increased its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 279.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 61,785 shares of the company's stock after purchasing an additional 45,509 shares during the period. Barclays PLC owned approximately 0.13% of Axsome Therapeutics worth $5,552,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Wellington Management Group LLP increased its holdings in shares of Axsome Therapeutics by 1.1% in the 3rd quarter. Wellington Management Group LLP now owns 742,745 shares of the company's stock worth $66,750,000 after buying an additional 8,125 shares during the last quarter. Iron Triangle Partners LP purchased a new position in Axsome Therapeutics in the third quarter worth about $22,671,000. Erste Asset Management GmbH bought a new stake in Axsome Therapeutics during the third quarter worth approximately $986,000. Point72 Europe London LLP raised its position in Axsome Therapeutics by 12.5% during the third quarter. Point72 Europe London LLP now owns 34,570 shares of the company's stock valued at $3,107,000 after purchasing an additional 3,829 shares during the period. Finally, PDT Partners LLC purchased a new stake in Axsome Therapeutics during the third quarter valued at approximately $1,052,000. Hedge funds and other institutional investors own 81.49% of the company's stock.

Axsome Therapeutics Stock Up 1.1 %

Shares of AXSM traded up $0.99 during midday trading on Friday, reaching $90.73. 956,380 shares of the stock were exchanged, compared to its average volume of 610,942. The company has a market capitalization of $4.40 billion, a P/E ratio of -13.89 and a beta of 1.18. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. Axsome Therapeutics, Inc. has a 52 week low of $64.11 and a 52 week high of $105.00. The company's 50 day moving average is $93.65 and its two-hundred day moving average is $87.98.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The business had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. During the same quarter in the previous year, the business posted ($1.32) EPS. On average, sell-side analysts anticipate that Axsome Therapeutics, Inc. will post -4.6 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Cantor Fitzgerald reissued an "overweight" rating and set a $121.00 target price on shares of Axsome Therapeutics in a research report on Thursday, December 12th. Wells Fargo & Company began coverage on shares of Axsome Therapeutics in a research note on Tuesday, September 3rd. They issued an "overweight" rating and a $140.00 target price on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $130.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, November 12th. Robert W. Baird increased their price objective on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th. Finally, StockNews.com raised shares of Axsome Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $125.93.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.